# *Improving the reporting of economic evaluation in osteoporosis: the value of CHEERS 2022 statement*

**Authors:** Mickael Hiligsmann1, Nannan Li1, Cyrus Cooper2, Jean-Yves Reginster3, Stuart Silverman4, Chris Carswell5, Don Husereau6

**Affiliations**

1. Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands

2. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK

3. WHO Collaborating Center for Public Health aspects of musculo-skeletal health and ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Belgium

4. Cedars-Sinai Medical Center, Los Angeles, US

5. Adis Journals, Springer Nature, Auckland, New Zealand

6. University of Ottawa, School of Epidemiology and Public Health, Ottawa, Ontario, Canada and Institute of Health Economics, Edmonton, Alberta, Canada

**Corresponding author**

Mickael Hiligsmann, Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands

Duboisdomein 30, 6229 GT, Maastricht, the Netherlands

[m.hiligsmann@maastrichtuniversity.nl](mailto:m.hiligsmann@maastrichtuniversity.nl)

**Keywords:**CHEERS; Cost-effectiveness; Economic evaluation; Osteoporosis; Reporting

# Editorial

Considering the limited availability of healthcare resources alongside major innovations in the management of osteoporosis, economic evaluations have played an increasing role in decision-making. Studies have particularly been conducted to assess the cost-effectiveness of anti-osteoporosis medications [1,2], fracture liaison services [3], screening strategies [4,5], or to define intervention thresholds [6]. The low quality of input parameters and poor reporting of these economic evaluations may however hamper their use by decision-makers and health professionals.

Using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement [7] (which was regarded as minimum amount of information required for reporting economic evaluations), in 2015, Hiligsmann et al. [1] assessed the quality of reporting of cost-effectiveness analyses of anti-osteoporosis medications published between 2008 and 2013, revealing that the quality of reporting was largely insufficient for several articles.

In 2019, a working group [8] was convened by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation (IOF) to provide guidance for the design, conduct, and reporting of economic evaluations in osteoporosis to improve their transparency, comparability, and methodologic standards. Acknowledging the importance of reporting, and the widespread recognition and acceptance of the CHEERS statement (published in 2013), the working group specifically recommended the use of the CHEERS statement for reporting any economic evaluation in the field of osteoporosis. In addition to CHEERS, the ESCEO-IOF guideline also recommended to report on and justify nine osteoporotic-specific reporting criteria. Since the publication of the ESCEO-IOF guideline, some cost-effectiveness studies in the field osteoporosis [9–12] have included CHEERS and/or the osteoporotic-specific reporting checklist as an appendix for reporting their study, while others [13–15] indicated that they followed the ESCEO-IOF guideline and adhered to CHEERS.

Since the original publication of the CHEERS statement, there have been several motivations to undertake an update [16]. Consequently, CHEERS has been replaced by the CHEERS 2022 statement [16], that consists now of a 28-item checklist, and an explanation and elaboration report with accompanying user tools and guidance Compared to CHEERS 2013, new items have been added in CHEERS 2022 and relate to stakeholder (patients or service recipients, general public, community) involvement, reporting and availability of a health economic plan and characterization of distributional effects. The last is especially important in the field of osteoporosis as the cost-effectiveness could widely differ across marginalized patient populations, such as the very old, or women. In addition, the original language has been broadened to improve the applicability of CHEERS, and sharing of unlocked models is encouraged to improve the transparency.

Recognizing the need and value of these changes, we support and highly recommend the use of CHEERS 2022 statement (in replacement to CHEERS) to report any economic evaluation in the field of osteoporosis, and to complement it with the nine osteoporosis-specific reporting criteria from the ESCEO-IOF guideline. Improving the reporting of economic evaluations will only serve to improve their transparency and quality, leading ultimately to increased trust, value, and use by decision makers.

# Conflict of interest

The authors have no conflict of interest relevant to this editorial.

# References

1. Hiligsmann M, Evers SM, Ben Sedrine W, et al. A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. *Pharmacoeconomics*. 2015;33(3):205-224. doi:10.1007/s40273-014-0231-1

2. Li N, Cornelissen D, Silverman S, et al. An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis. *Pharmacoeconomics*. 2021;39(2):181-209. doi:10.1007/s40273-020-00965-9

3. Wu CH, Kao IJ, Hung WC, et al. Economic impact and cost-effectiveness of fracture liaison services: a systematic review of the literature. *Osteoporos Int*. 2018;29(6):1227-1242. doi:10.1007/s00198-018-4411-2

4. Nayak S, Roberts MS, Greenspan SL. Cost-Effectiveness of Different Screening Strategies for Osteoporosis in Postmenopausal Women. *Ann Intern Med.*2011 Dec 6;155(11):751-61. doi:10.7326/0003-4819-155-11-201112060-00007

5. Turner DA, Khioe RFS, Shepstone L, et al. The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study. *J Bone Miner Res*. 2018;33(5):845-851. doi:10.1002/jbmr.3381

6. Kanis JA, Harvey N, Cooper C, et al. A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. *Arch Osteoporos*. 2016;11(1). doi:10.1007/s11657-016-0278-z

7. Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. *Value Heal*. 2013;16(2):e1. doi:10.1016/j.jval.2013.02.010

8. Hiligsmann M, Reginster J, Tosteson ANA, et al. Recommendations for the conduct of economic evaluations in osteoporosis : outcomes of an experts ’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis , Osteoarthritis and Musculoskeletal Diseases (ESCEO). *Osteoporos Int.* 2019;30(1):45-57.  doi: 10.1007/s00198-018-4744-x.

9. Cui L, He T, Jiang Y, et al. Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data. *Osteoporos Int*. 2020;31(2):307-316. doi:10.1007/s00198-019-05173-6

10. Mori T, Crandall CJ, Fujii T, Ganz DA. Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan. *Arch Osteoporos*. 2021;16(1). doi:10.1007/s11657-021-00956-z

11. Mori T, Crandall CJ, Fujii T, Ganz DA. Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan. *Arch Osteoporos*. 2021;16(1). doi:10.1007/s11657-021-00956-z

12. Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY. Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. *Semin Arthritis Rheum*. 2019;49(2):184-196. doi:10.1016/j.semarthrit.2019.01.006

13. Hiligsmann M, Maggi S, Veronese N, Sartori L, Reginster JY. Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. *Osteoporos Int*. 2021;32(3):595-606. doi:10.1007/s00198-020-05802-5

14. Ito K. Cost-effectiveness of Screening for Osteoporosis in Older Men With a History of Falls. *JAMA Netw open*. 2020;3(12):e2027584. doi:10.1001/jamanetworkopen.2020.27584

15. Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY. Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective. *Semin Arthritis Rheum*. 2020;50(3):394-400. doi:10.1016/j.semarthrit.2020.02.004

16. Husereau D, Drummond M, Augustovski F, et al.; CHEERS 2022 ISPOR Good Research Practices Task Force Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health. 2022 Jan;25(1):3-9.